Form 4: Pasithea Therapeutics CEO Tiago Marques Sells 960 Shares Due to Brokerage Account Closure

Pasithea Therapeutics CEO Tiago Marques sold 960 shares of common stock at $0.825 per share due to the closure of a foreign brokerage account.

Summary

• On May 12, 2025, Tiago Marques, CEO of Pasithea Therapeutics Corp., sold 960 shares of common stock.
• The sale occurred because a foreign brokerage account holding these shares was being wound down.
• The shares were sold at a price of $0.825 per share.
• Following the transaction, Marques directly owns 40,001 shares of Pasithea Therapeutics Corp.
• The reported share numbers have been adjusted to reflect a 1-for-20 reverse stock split that occurred on January 2, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction appears to be driven by personal circumstances (brokerage account closure) rather than a strategic decision related to the company's performance.

Industry Context

This transaction is a routine disclosure of stock sales by a company executive and doesn't necessarily indicate a broader trend within the pharmaceutical industry.

Stakeholder Impact

• The sale of a small number of shares by the CEO is unlikely to have a significant impact on shareholders.

Key Dates

Keywords

Pasithea Therapeutics, Tiago Marques, stock sale, Form 4, CEO, KTTA, reverse stock split, brokerage account